DLinDMA (Synonyms: 1,2-Dilinoleyloxy-N,N-dimethyl-3-aminopropane) |
Catalog No.GC33476 |
DLinDMA is a key lipid component of stable nucleic acid lipid particles as a benchmark.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 871258-12-7
Sample solution is provided at 25 µL, 10mM.
DLinDMA is a key lipid component of stable nucleic acid lipid particles as a benchmark. DLinDMA can be used to deliver siRNA[1].
DLinDMA liposomal formulation was nontoxic at lower concentrations. A significant decrease in cell proliferation was only observed at the highest concentration 200 µM for DOTAP and at concentrations ranging from 25 to 200 µM for DLinDMA liposomal formulations[2]. In a macrophage cell-line, LNP containing DLinKC2-DMA, DLinKDMA, or DLinDMA, which lack ester linkages, are not vulnerable to lipase digestion and facilitate much more potent gene silencing[3].
As a key lipid component of nucleic acid lipid granules (SNALP), DLinDMA can deliver small interfering RNA (siRNA) in mice[1].
References:
[1]. Semple SC, Akinc A,et,al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010 Feb;28(2):172-6. doi: 10.1038/nbt.1602. Epub 2010 Jan 17. PMID: 20081866.
[2]. Vemana HP, Saraswat A, et,al. A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes. Nanomedicine (Lond). 2021 Jun;16(13):1081-1095. doi: 10.2217/nnm-2020-0477. Epub 2021 May 7. PMID: 33960213; PMCID: PMC8162161.
[3]. Lin PJ, Tam YY, et,al.Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine. 2013 Feb;9(2):233-46. doi: 10.1016/j.nano.2012.05.019. Epub 2012 Jun 12. PMID: 22698807.
Average Rating: 5
(Based on Reviews and 7 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *